ArticleFrontiers in cell and developmental biology2026
Celecoxib and shikonin loaded dissolving microneedle exert analgesic, anti-inflammatory and chondroprotective activity for osteoarthritis treatment.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis (OA) is a chronic degenerative disease that severely affects the physical function and quality of life of patients. Non-steroidal anti-inflammatory drugs (NSAIDs) are standard treatments for OA, alleviating joint pain and inflammation. Meanwhile, long-term oral administration and intra-articular injection will bring inevitable side effects. In this study, a dissolving microneedle composite drug delivery system co-loaded with celecoxib and shikonin (SKN-CXB@MN) was prepared, which can efficiently deliver drugs through the skin and exert therapeutic effects on OA from multiple targets including analgesia, anti-inflammation, and cartilage protection. Methods: The material properties of SKN-CXB@MN were assessed through experiments on morphology, mechanical properties, solubility, drug release performance, and skin recovery. The biocompatibility of SKN-CXB@MN was determined using CCK-8 assays and live-dead staining. The protective effect of SKN-CXB@MN on IL-1β-induced chondrocytes were investigated through Results: Materials characterization reveals that SKN-CXB@MN possesses sufficient mechanical strength to penetrate the skin. Upon application, the microneedles dissolve completely and release 85% of CXB and 75% of SKN within 15 min . Conclusion: The dual-drug loaded SKN-CXB@MN system facilitates targeted drug delivery, thereby reducing systemic side effects. The synergistic effects of Celecoxib (CXB) and Shikonin (SKN) not only substantially alleviate pain and inflammation but also retard cartilage degeneration by modulating chondrocyte apoptosis and extracellular matrix metabolism. These multifaceted mechanisms indicate that the SKN-CXB@MN formulation could be a promising therapeutic option for osteoarthritis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.